- Optimi Health (CSE:OPTI) has reached a significant milestone by having successfully harvested eight new natural psilocybin genetics
- Optimi has cultivated new psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates
- The company also announced that its GMP Psilocybin API for encapsulation is available in standardized dosages or for sale to other groups as a raw material for their formulations
- Optimi Health Corp. last traded at $0.19 per share
Optimi Health (CSE:OPTI) has reached a significant milestone by having successfully harvested eight new natural psilocybin genetics.
The Vancouver-based company stated this strengthens its position as a pioneering force in the psychedelic research and formulation space.
Optimi has cultivated new psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. The new genetic strains were cultivated by Optimi’s cultivation manager, Scott Marshall, who oversees its large-scale operations, genetic advancement, and the stabilization of novel and existing varieties of Psilocybe cubensis.
Optimi also announced that its full spectrum, Good manufacturing practices (GMP) extract quality program has completed process validation for the natural psilocybin drug candidate, and the stability testing according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines continues. With more than three months of accelerated data, the company confirms the product is able to maintain potency and other quality attributes for the duration of clinical trials.
“Our production of a scalable GMP-compliant extract is a crucial step towards facilitating further research and maintaining our position as a reliable and innovative partner in the development of psilocybin-based therapies,” Optimi CEO Bill Ciprick said in a news release.
The company also announced that its GMP Psilocybin API for encapsulation is available in standardized dosages or for sale to other groups as a raw material for their formulations. This marks a significant step in expanding the company’s reach and impact within the psychedelic research community.
Optimi Health Corp. is a drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and functional mushrooms that focus on the health and wellness markets.
Join the discussion: Find out what everybody’s saying about BlackBerry stock on the Optimi Health Corp. Bullboard and check out the rest of Stockhouse’s stock forums and message boards.
Optimi Health Corp. last traded at $0.19 per share and its stock is up 8.57 per cent over the past month.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
